A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease
What is the purpose of this trial?
The purpose of this study is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of Alzheimer's Disease(AD). The primary study hypotheses are that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Assessment Scale Cognitive Subscale(ADAS-Cog) score and that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory(ADCS-ADL) score.
- 55 Years - 85 Years
- Last Updated:
- Study HIC#: